Physician profile
Aref Daouk
NPI 1811376734
$1,604.85
in general payments reported to CMS, 2019-2025
20 companies · $1,099 in 2025
The $1,099 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $16.35 · 2023: $201 · 2024: $288 · 2025: $1,099.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,589.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,588.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $407.30 | 2024-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $330.66 | 2023-2025 | Nucala, Trelegy Ellipta |
| Amgen INC. | $125.75 | 2023-2025 | Tezspire, Tavneos |
| Genzyme Corporation | $111.36 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $91.84 | 2023-2025 | Dupixent |
| Verona Pharma, INC. | $73.55 | 2025 | Ohtuvayre |
| Insmed, INC. | $70.65 | 2024-2025 | Arikayce |
| Ani Pharmaceuticals, INC. | $65.49 | 2025 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.21 | 2023-2025 | Jardiance, Jascayd, Ofev |
| Viatris Specialty LLC | $38.27 | 2025 | Yupelri |
| Axsome Therapeutics, INC. | $35.29 | 2023 | Sunosi |
| United Therapeutics Corporation | $35.08 | 2024-2025 | Tyvaso, Tyvaso |
| Boston Scientific Corporation | $34.66 | 2023-2025 | Watchman Flx, Watchman |
| Inspire Medical Systems, INC. | $32.11 | 2025 | Inspire |
| Csl Behring | $24.20 | 2025 | Hizentra |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $19.82 | 2025 | Xolair |
| Electromed, INC. | $16.95 | 2025 | Smartvest |
| Takeda Pharmaceuticals U.S.A., INC. | $15.47 | 2024 | Aralast |
| Mylan Specialty L.P. | $14.93 | 2024 | Yupelri |
| Pulmonx Corporation | $14.26 | 2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aref Daouk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.